About Blossom
Following psychedelic research from lab to clinic
Since 2018, Blossom has tracked the clinical trials, published research, and regulatory shifts moving psychedelic medicine into mainstream healthcare. This is a long-term project built to document one of the most consequential developments in mental health in a generation.
The person behind it
Floris Wolswijk
I started tracking psychedelic research in 2018, well before the current wave of mainstream attention. What began as an effort to make sense of a rapidly expanding but fragmented field gradually became Blossom: a structured database for anyone who needs to understand what the science actually says.
Alongside running Blossom, I work as a part-time facilitator, supporting people through psychedelic experiences in therapeutic contexts. I also consult with Delphi, working with organizations navigating the psychedelic landscape strategically.
These roles inform each other. Being close to the practice side of the field sharpens what I choose to track and how I think about what actually matters.
What Blossom tracks
From research to access
Psychedelic medicine moves through a predictable pipeline: evidence is generated, then translated into clinical frameworks, and eventually reaches the people who need it. Blossom covers the entire arc.
Research
Clinical trials generate the evidence base. Peer-reviewed papers define what works, for whom, and at what dose. Blossom tracks every study, from early Phase I safety work to pivotal Phase III programs, so you can follow the science as it builds.
Translation
Evidence alone does not create access. Regulatory submissions, therapy protocol development, training standards, and institutional frameworks all need to be established. Blossom follows how scientific findings get turned into viable treatments.
Access
The real-world test of research is whether people can reach treatment. Legal frameworks, country-by-country policy shifts, clinic openings, and reimbursement pathways all determine who benefits and when. Blossom maps this territory in real time.
March 2026
Blossom, rebuilt
In early 2026 I relaunched Blossom with a substantially upgraded dataset, a new product experience, and a clearer framing for what the database is actually for. The research landscape has matured considerably since 2018: more trials, more regulatory movement, more real-world access questions coming into focus. The database needed to mature with it.
The relaunch brings improved search, better structured data, expanded coverage of access and policy developments, and a membership model that helps keep the work sustainable.
Support the work
Help keep the database running
Blossom is largely a one-person operation. Memberships are what make it possible to maintain the database, track new research as it emerges, and build out the features the field needs. If you find value in the work, consider supporting it.